Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Twelve Lecture Series on Medical 3D BioPrinting Applications & Technologies by LPBI’s Medical 3D Printing Team, aka M3DP

Curator: Aviva Lev-Ari, PhD, RN

• We are accelerating our involvement with OUR OWN CONCEPT for a GLOBAL DISTRIBUTORSHIP of Multivendor Products and Services in Medical 3D BioPrinting.

• We are developing our Team Member’s Capabilities and Intellectual Property (IP) in the domain of 

Medical 3D BioPrinting Applications & Technologies

• Medical 3D Printing

http://pharmaceuticalintelligence.com/medical-3d-printing/

• Medical MEMS, Sensors and 3D Printing: Frontier in Process Control of BioMaterials

http://pharmaceuticalintelligence.com/2015/08/10/medical-mems-sensors-and-3d-printing- frontier-in-process-control-of-biomaterials/ 

—>>>>> We need IP to address INVESTORS <<<<< —

We have in LPBI’s DropBox a Password Protected Folder for Team Member’s IP in Medical 3D Printing

SCHEDULE for PRESENTATIONS in the coming Fifteen weeks for our Weekly Meetings of LPBI’s Medical 3D Printing Team, aka M3DP

ALL PRESENTATION ARE ON SKYPE on Thursdays @9:30AM EST

= 3:30PM Swiss Time = 4:30PM Israel Time 

PART ONE:

Schedule of Presentations

PART TWO:

M3DP Staff Meeting Agenda per Presentation Day

PART ONE:

Schedule of Presentations

#1: date: 8/13/2015 DONE

Presenter: Aviva

Topic: Medical 3D Printing Applications & Technologies, Tools & Processing 

#2: date: 8/20/2015 CONFIRMED – DONE

Presenter: Steve Lerner

Topic: Medical 3D Printing & Programmable Sensors

#3: date: 8/27/2015 – DONE

Presenter: Dr. Pearlman

Topic: Medical 3D Printing: Thought Leadership for Products and Services

#4: date: 9/3/2015 – DONE

Presenter: Dr. Stephen J Williams

Topic: Medical 3D Printing and BioInks -DONE

http://pharmaceuticalintelligence.com/2016/04/04/bio-inks-and-3d-bioprinting/

#5: date: 9/10/2015 – Aviva’s Presentation

AGENDA for 9/10

• GDE

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/

• Matrix Organization for M3DP

http://pharmaceuticalintelligence.com/2015/08/26/lpbis-m3dp-matrix-organization/

#6: date: 9/24/2015 – DONE

Presenter: Irina Robu, PhD

Topic: Medical 3D Printing for Tissue Engineering 

#7: date: 10/1/2015 CONFIRMED

Topic: Presenter: Irina Robu, PhD

Medical 3D Printing for Tissue Engineering

#8: date: 10/8/2015 CONFIRMED

Presenter: Bill Zurn

Topic: Medical 3D Printing and MEMS 

#9: date: 10/15/2015 CONFIRMED

Presenter: Tilda Barliya, PhD

Topic: Medical 3D Printing and Tissue Engineering in Israel 

#9A: date: 10/16/2015 THREE Presentations CONFIRMED

Presentation #1: Rosalind Codrington, PhD – 60 minutes

Cell Selection using Intracellular Targets

Presentation #2: Evelyna Cohn, PhD – 30 – minutes

Glycoprotein and 3D BioPrinting

Presentation #3: Stephen J Williams, PhD and Dharmendra Goswami, PhD – 30 Minutes

Gene Therapy: CRISPR and 3D BioPrinting

#10: date: 10/22/2015 CONFIRMED

Presenter: Danut Dragoi

Topic: Medical 3D Printing and Metals in use in Medical Devices 

#11: date: 10/29/0215 CONFIRMED

Presenter: Gerard Loiseau

Topic: Medical 3D Printing and Dental 

#12: date: 11/5/2015 CONFIRMED

Presenter: Dr. Raphael Nir

Topic: Medical 3D Printing and Cytokines 

#13: date: 11/12/2015 CONFIRMED

Presenter: Dr. Dharmendra Goswami

Topic: CRISPR and The Future of Gene Therapy

#14: date 11/19/2015 CONFIRMED

Presenter: Rosalind Codrington, PhD – 60 minutes

Topic: Immunology, Magnetic Beads and 3D BioPrinting

DECEMBER 2015

BioMEMS and 3D BioPrinting

PART TWO:

M3DP Staff Meeting Agenda per Presentation Day

#1: date: 8/13/2015 DONE

Presenter: Aviva

Topic: Medical 3D Printing Applications & Technologies, Tools & Processing 

LPBI’s Perspective on Medical and Life Sciences Applications – 3D Printing: BioInks, BioMaterials-BioPolymer

http://pharmaceuticalintelligence.com/2015/08/12/lpbis-perspective-on-medical-and-life-sciences-applications-3d-printing-bioinks-biomaterials-biopolymer/

LPBI’s Perspective on Technologies Platforms & Tools in the Production and Process Control of Components & Systems using BioMaterials, BioPrinting and BioFabrication

http://pharmaceuticalintelligence.com/2015/08/12/lpbis-perspective-on-technologies-platforms-tools-in-the-production-and-process-control-of-components-systems-using-biomaterials-bioprinting-and-biofabrication/

#2: date: 8/20/2015 CONFIRMED – DONE

Presenter: Steve Lerner

Topic: Medical 3D Printing & Programmable Sensors

AGENDA for 8/20

AGENDA

First – Steven Presentation

Second – Group Q&A 

Third – Aviva provides Updates on:

• Business activity briefing on meetings with potential investors
• Code of Professional Conduct in Meeting with Investors
• Ontology Augmentation requirements
• Curation Methodology DEMO by Aviva – to be scheduled
• Business Card design for the Medical 3D Team
• Code of Professional Conduct when your are Designated a Mentor to a member of the Team
• DropBox Password Folder to host ALL TEAM MEMBERS’ Presentation on APPLICATIONS
• DropBox Password Folder for Dr. Pearlman’s Intellectual Property Not related to Medical 3D Printing [all Past Pages to be stored here]
• DropBox Password Folder for Dr. Pearlman’s Intellectual Property on PRODUCT DESIGN for Medical 3D Printing APPLICATIONS

Fourth – Dr. Williams: Process and Scope of Using Twitter.com to reach wide audience of topics under research at LPBI

Fifth – Dr. Pearlman briefing (postponed to next week meeting)

#3: date: 8/27/2015 DONE

Presenter: Dr. Pearlman 

Topic: Medical 3D Printing: Thought Leadership for Products and Services

http://pharmaceuticalintelligence.com/2015/09/03/invention-3d-reparative-transforming-biostent-concept-description-2/

AGENDA for 8/27

1. Announcement — Dr. Tilda has Join as Nanotechnology in Drug Delivery Expert and M3DP interface with the 23 Isreali Tissue Engineering Start Ups. Yoel Ezra provide Engineering support to Tilda

2. Briefing on Our Pipeline: Presentations to Investors and Feedback from Investors

http://pharmaceuticalintelligence.com/2015/08/26/feedback-from-investors-rnewmanshieldsco-com-for-lpbi-presentation-on-8182015/

3. Dr. Pearlman’s Presentation on Cardiovascular Applications of 3D Printing

4. Aviva Presents: INTERNAL CANDIDATE Application FORM and the Application PROCESS for two types of Openings:

4.1  Co-Founder

and/or

4.2  Prospectus Signatory

http://pharmaceuticalintelligence.com/2015/08/26/m3dp-co-founder-and-prospectus-signatories/

5. Aviva Presents

5.1  LPBI’s M3DP – Matrix Organization

http://pharmaceuticalintelligence.com/2015/08/26/lpbis-m3dp-matrix-organization/

5.2 Template for M3DP Website – http://m.bocsci.com/

5.3  EXTERNAL Candidate Openings: CEO, COO, CFO

#4: date: 9/3/2015 DONE

Presenter: Dr. Stephen J Williams

Topic: Medical 3D Printing and BioInks

AGENDA for 9/3

1, Announcement — New Organizational Chart for GDE – Global Holding Company – is postponed to 9/10/2015

2.  Briefing on Our Pipeline: Presentations to Investors 

http://pharmaceuticalintelligence.com/investor-relations/

3.  Dr. Stephen J Williams  Topic: Medical 3D Printing: FDA Policy and BioInks – See Dropbox for Materials Shared in the Presentation

4.  REMINDER: 9/10 DEADLINE for INTERNAL CANDIDATE Application FORM and the Application PROCESS for two types of Openings:

4.1  One Co-Founder

and/or

4.2  Four Prospectus Signatory

http://pharmaceuticalintelligence.com/2015/08/26/m3dp-co-founder-and-prospectus-signatories/

5. Aviva Presents UPDATES for our Repository for LPBI’s Initiative on Medical 3D Printing

http://pharmaceuticalintelligence.com/2015/08/18/repository-for-lpbis-initiative-on-medical-3d-printing/

6. Aviva Presents RoadMap – Presentation to Investors: Five Businesses @ Leaders in Pharmaceutical Business Intelligence AFTER 9/10/2015 GDE will replace this content

http://pharmaceuticalintelligence.com/2015/08/17/presentation-to-investors-five-business-leaders-in-pharmaceutical-business-intelligence/

7. AFTER Labor Day we will start the Project of Medical 3D BioPrinting – Ontology Augmentation, ALL Members of M3DP Technical Staff are expected to PUBLISH on the Journal One Post of One Page Per Week in the Domain assigned, see below

7.1 Please request One-on-One Tutorial on “HOW to Publish on our Platform”

7.2 Each Members of M3DP Technical Staff is welcomed to send me TWO MS Word files of theirs First and Second Posts, I will help them with Editing and with Posting, so they will do so by themselves ALONE in the future. It is OK to post alone and anticipate for Aviva to review, edit and teach you style. See attachment

The Ontology of Medical 3D Printing Research Category on the PharmaceuticalIntelligence.com Journal is developed and maintained by:

7.3 If you wish to withdraw from the M2DP Team – e–mail Aviva which other business you wish make contributions to, choose from list of LPBI businesses in this LINK

http://pharmaceuticalintelligence.com/2015/08/17/presentation-to-investors-five-business-leaders-in-pharmaceutical-business-intelligence/

7.4 If you wish to switch to INACTIVE – e–mail Aviva, this is option for Experts, Authors, Writers since they have weekly posting requirements. 

7.5  if you wish to withdraw from Business Development role — Please schedule Skype with Aviva

7.6  if after 7.5 you wish to receive e-mails and announcements — Please Skype with Aviva

8. We will start a Market Intelligence Project like we did for RegenHU but for Europe — The outcome may Yield Leads for Consulting assignements

If this is your interest, work with Aviva on a Geography and your Specified Products and segments: Biotech or Medical Devices

#5: date: 9/10/2015 – Aviva’s Presentation

AGENDA for 9/10

• GDE

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/

• Matrix Organization for M3DP

http://pharmaceuticalintelligence.com/2015/08/26/lpbis-m3dp-matrix-organization/

• VIDEOS Cardiovascular Applications of 3D BioPrinting

  Using 3D printed models for planning and guidance during endovascular intervention (VIDEO)

   VIEW VIDEO

  http://www.3dbioprintingconference.com/surgery/using-3d-printed-models-for-planning-and-guidance-during-endovascular-intervention-video/

  Bioprinted Valves That Grow: How 3D Printing is Transforming Heart Surgery (VIDEO)

  VIEW VIDEO

  http://www.3dbioprintingconference.com/3d-bioprinting/bioprinted-valves-that-grow-how-3d-printing-is-transforming-heart-surgery/

• CONFERENCES – Comparative Agendas for 3D in Medicine – Three Conferences

  Cell Therapy Manufacturing and Gene Therapy Conference, December 2-3, 2015, Sheraton Airpost Hotel, Brussels, Belgium

  http://pharmaceuticalintelligence.com/2015/09/06/cell-therapy-manufacturing-and-gene-therapy-conference-december-2-3-2015-sheraton-airpost-hotel-brussels-belgium/

  2015 4th TERMIS World Congress, September 8-11, 2015, Boston Marriott Copley Place

  http://pharmaceuticalintelligence.com/2015/07/22/2015-4th-termis-world-congress-september-8-11-2015-boston-marriott-copley-place/

  Future of 3D Printing in Medicine: The Role of Bioactive Materials @ the NJ Symposium for Biomaterials Science on November 9, 2015 — Heldrich Hotel, New Brunswick, NJ

  http://pharmaceuticalintelligence.com/2015/07/30/future-of-3d-printing-in-medicine-te-role-of-bioactive-materials-the-nj-symposium-for-biomaterials-science-on-november-9-2015-heldrich-hotel-new-brunswick-nj/

Aviva at Stanford, CA 9/16 –9/20 – No Weekly Meeting

Every Team member please post One Page per Week in your Ontology Category of Research

#6: date: 9/24/2015 CONFIRMED

Presenter: Irina Robu, PhD

Topic: Medical 3D Printing for Tissue Engineering

AGENDA for 9/24

http://pharmaceuticalintelligence.com/gde-news/

#7: date: 10/1/2015 CONFIRMED

Topic: Presenter: Irina Robu, PhD

Medical 3D Printing for Tissue Engineering

AGENDA for 10/1/2015

Following our 9:30AM EST Presentation by Irina Robu, PhD on Tissue Engineering, the 101/2015 Agenda has THREE Parts:

PART ONE: at 11AM EST = 4PM UK = 5PM Swiss Time = 6PM Israel Time

PART TWO:

GDE’s PROPOSAL for The Parker Foundation

PART THREE:

Summary of Decisions Taken on 9/28/2015 – Five meetings with Board Member, Prof. Marc Feldman, Stanford University

PART ONE

Presentation about Technologies at TechInnovate, an Incubator incorporated in Delaware in operation as a Virtual Global Start Up, now considering GDE’s Deals, Funding and Partnership business to arrange for Placement of $35Million to start as discussed with Aviva on 9/30/2015.

Presenter: CEO, Mike Eisen, Belfast, Northern Ireland

In attendance at Mike Eisen’s Presentation:

From: TechInnovate: Inventor and Patent Holder: Dr. Evelyna Cohn and Mitchell Heldt 

From: GDE’s M3DP — All Members of the Team

Topic: BioMaterial and Devices High Tech Product Concept under Provisional Patents of been Patents awarded

a. A Cardio Pump externally activated

NEED: Funding

b. Leaf Sensor and Ground Sensor for Plant implantation as Soil conditions controllers and data acquisition collectors transmitting data signals to drones over the agriculture field

NEED: a Funding

NEED: Partnership with Alpha SzenSzors, Inc. for manufacturing of Sensors

c. Under PPA filed in the UK, A Security /Defence Product COncept, TriGel – a 3-4 layer Bio MATRIX GEL Inhibitor of explosive devices

NEED: Funding

Consideration: Partnership with GDE’s M3DP for a JOINT Design using 3D BioPrinting for the Additive Layering Manufacturing Process.

DEMAND: US, UK and Israel DoD

d. Hematological Diagnostics Kits for RBC in Serum

PART TWO

GDE’s PROPOSAL for The Parker Foundation

The Parker Foundation which focuses on three areas: Life Sciences, Global Public Health and Civic Engagement. In 2015, Mr. Parker announced a $600 million contribution to launch the foundation.

The Parker Foundation was established through a $600 million gift by Sean Parker. The foundation builds upon Sean’s historical philanthropic support and capitalizes on his pioneering work in the fields of technology, media, company building, and public policy. Based in San Francisco, the foundation intends to aggressively pursue large-scale systemic change in three focus areas: Life Sciences, Global Public Health, and Civic Engagement.

Since 2005, Sean has been an active donor to cancer research, global public health and civic engagement. In 2012, he pledged a $5 million grant to Stand Up to Cancer and the Cancer Research Institute to create the Immunotherapy Dream Team, uniting laboratory and clinical efforts that will lead to the immunological treatment, control and prevention of cancer.

More recently, Sean pledged $24 million to create the Sean N. Parker Center for Allergy Research at Stanford and made a $4.5 million grant to support Malaria Elimination Initiative at the University of California San Francisco’s Global Health Group. In February 2015, Sean was ranked number 5 on the Chronicle of Philanthropy’s 2014 Philanthropy 50 list.

I am suggesting the following: addresses to this e-mail to serve as committee

We have Team members not on the committee, which will submit input to the proposal discussed below

(ALL Presenters on the “Lecture Series” are GDE Team Member)

Let’s all have a Skype scheduled session on the details, below

SKYPE MEETING WITH PROF. FELDMAN on 10/29 8AM PST

The Team need to have READY the GDE’s DRAFT PROPOSAL for The Parker Foundation. Each Team Member needs to prepare OWN input to the ONE Proposal to be submit by GDE.

We will discuss few concepts of ours regarding a PROPOSAL we wish to submit to Sean Parker Foundation, about our

1. Scientific Media Business in Life Sciences, Medicine and Biotech

1.1 the 3300 Scientific Journals

1.2 the 16 Titles in Medicine

1.3 the Real Time Conference Coverage of Biotech and Medicine Conferences (methodology developed at LPBI by Aviva & Dr. Williams using Social Media is Scaleable)

2. M3DP 

2.1 R&D in Biologics and Tissue Engineering

2.2 Medical Devices and 3D BioPrinting

(Our Lecture Series is in fact a portfolio of CONCEPTS for businesses based on 2.1 and 2.2)

2.3 Genomics, Gene Editing and 3D BioPrinting

We will contact the Parket Foundation AFTER all addresses Skyped with Prof. Feldman about the PROPOSAL Concept of their own input contributed sections of the Proposal

Thank you, Gerard for that significant LEAD.

Outcomes of the Skype session, will result in a second session with all members of the Team

PART THREE:

Summary of Decisions Taken on 9/28/2015 – Five meetings with Board Member, Prof. Marc Feldman, Stanford University

PART THREE

Summary of Decisions Taken on 9/28/2015 – Five meetings with Board Member,

Prof. Marc Feldman, Stanford University

Skype with Mr. Werring, Amsterdam, NL

– we will have a follow up meeting with Gerard and Aviva to discuss further steps in Mr. Werring exploration Joining our Team to Develop Business Relations between GDE and Elsevier, NL for our Scientific Media Strategic Business Unit, DBA, Leaders in Pharmaceutical Business Intelligence (LPBI)

Mr. Werring will e-mail his availability

– Mr. Werring will explore opportunities for our 2nd Business Unit, Deals, Funding and Partnerships, exploration of Private Equity Investors for our portfolio of 20 Company-Clients.

Skype with Gerard and Marc

– Concept exchange on current and future plans

Aviva is suggesting quarterly brainstorming meetings

Skype with Dr. Pearlman

– Progress was made in understanding the process of IP development and the role of all playing parties in value creation on behalf of GDE and M3DP, in particular

Skype with Gil Press, Forbes

– Synergies among the Four Business Units were acknowledged

– Development of Business Plan for each Strategic Business Unit was proposed

– Alternative organizational structure discussed: highlighting the Pros of a Holding company with four independent subsidiaries vs. a company with four Strategic Business Units,

– Agreement was reached on the need to recruit C-level Executive for each Subsidiary

– Future potential coverage of M3DP and success in Funding Early Stage 20 ventures were identified as topics that Gil Press would be considering writing about in Forbes was discussed

Action Points: we will share milestones and seek Gil’s advice as progress been accomplished

In-Person Meeting with Dhermendra Goswami, PhD

– Potential joining the Team discussed

– Potential collaboration in the field of Gene Editing using 3D BioPrinting was discussed

– Discussed the needs of team building for M3DP’s R&D on Biologics, Tissue Engineering, Evolution, Genetic Diseases in Population or in Individuals as consulting services between the 3D Printers OEMs represented as Vendors and the end Users at Biotech, R&D Labs, Biobanks

Action Points:

– Aviva will call a meeting between Dr. Williams and Dr. Goswami – SCHEDULED FOR 10/7 9AM EST

– Dr. Goswami will consider joining the Team at GDE, M3DP, in particular

Putting all together, it was a day of Grand ideas, inspiration future plans and RESOLUTIONS of past issues.

#8: date: 10/8/2015 CONFIRMED

Presenter: Bill Zurn

Topic: Medical 3D Printing and MEMS

AGENDA for 10/8/2015

• Opportunities to develop concept and consider .gov funding

#9: date: 10/15/2015 CONFIRMED

Presenter: Tilda Barliya, PhD

Topic: Medical 3D Printing and Tissue Engineering in Israel

AGENDA for 10/15

• Skype about the George Institute: Australia and China
• Meeting @ Beacon Angels
• FOUR new EAWs will be added to Our Team
• Working with Yissum on 11 Ventures for the Excel File
• Added two ventures to Excel File: Woodland Pharamceuticals and SBH, Inc.
• Team working on Presentations for Natick Contacts 
• M3DP’s R&D Team is working of Glycoproteins, Gene Therapy and NanoBeads in Immuno-Diagnostics
• Dr. Sag submitted 9 Papers to Cancer Volume Two

#10: date: 10/22/2015 CONFIRMED

Presenter: Danut Dragoi

Topic: Medical 3D Printing and Metals in use in Medical Devices

AGENDA for

#11: date: 10/29/0215 CONFIRMED

Presenter: Gerard Loiseau

Topic: Medical 3D Printing and Dental

AGENDA for

#12: date: 11/5/2015 PENDING

Presenter: Dr. Raphael Nir

Topic: Medical 3D Printing and Cytokines

AGENDA for

#13: date: 11/12/2015 PENDING

Presenter: Dr. Dharmendra Goswami

Topic: CRISPR and The future of Gene Therapy

AGENDA for